Through its spin-off program, Helmholtz Enterprise finances the establishment of start-up teams and the implementation of start-up projects in the Helmholtz Association.

Leopard Biosciences GmbH, founded in July, is developing a new diagnostic platform that can detect multiple markers in a single test. The translation of the technology was made possible by funding from the Helmholtz Association.

Ten female-led startups competed in the finale of the Female StartAperitivo startup competition. Ascenion’s portfolio company TimeTeller received the most votes in the public ballot for a method to make chemotherapy more effective and less harmful to the patient.

Ascenion's portfolio company OMEICOS has received a significant grant by the German Federal Ministry of Education and Research (“BMBF”) to co-finance a Phase 2a study evaluating their lead product candidate OMT-28 in Primary Mitochondrial Disease (PMD) patients.

The Berlin start-up develops AI-based software for predicting complications after major cardiac surgery. New business angels and family offices have now invested in the company, alongside the existing investor consortium around IBB Ventures.

The investment round is led by TRUMPF Venture with the objective of translating iThera Medical’s optoacustic imaging technology into routine clinical use.

Recovery Cat has developed software to improve the care of around six million patients in Germany with severe mental disorders. The investors are IBB Ventures’ Impact Fonds, Springboard Health Angels and a family office from Heidelberg.

Bioventure and IFB Innovationsstarter GmbH are financing the Hamburg biotech company for the next four years – to build the necessary infrastructure for research and production.

Ascenion’s portfolio company has dosed the first patient with its lead candidate TK-8001, a new therapy to target MAGE-A1 positive solid tumours.

With the new round of funding, Aignostics aims to continue growing their team, putting a stronger focus on the US market, and accelerating their investment into their platform and regulatory excellence.

Dermagnostix will use the funds to launch its lead product PsorX in Europe and extend its game-changing approach for the molecular diagnosis of skin diseases to further indications.

• EUR 47 million committed by fund initiators Ascenion and Goethe-University together with the European Investment Fund (EIF), Evotec, and other investors
• Focus on high-potential, early-stage life-science start-ups and projects, sourced from Ascenion’s and Innovectis’ partner institutions and other European academic institutions
• 15 + 5 years timeframe enables the partners – and the institutions they represent – to participate in future profits
  
   

Supported by Ascenion, Felix Krenzien and his team at Charité – Universitätsmedizin Berlin attracted the grant from the Else Kröner-Fresenius-Stiftung (EKFS) to translate their new approach for quantifying extracellular NAD+ into medical practice.

Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes severe, difficult-to-treat respiratory infections.

Supported by Ascenion, Matthias Bruhn and his team at TWINCORE - Centre for Experimental and Clinicial Infection Research have attracted EUR 97,000 to explore the commercial feasibility of their MEMUMAB project. The goal is to provide therapeutic antibodies against infectious diseases such as COVID-19.

The company will use the proceeds to advance its groundbreaking optoacoustic imaging technology into clinical practice. If successful, it would provide a superior, non-invasive alternative to established diagnostic procedures in many diseases.

The German Federal Ministry of Education and Research (BMBF) is providing EUR 6.5 million in funding for 10 selected research projects targeting long-term symptoms of COVID-19. Ascenion’s partner institutes are making significant contributions to three of these projects.

25 August 2021, Munich – Cardior Pharmaceuticals has closed a Series B financing round totalling EUR 64 million (USD 76 million). The round was led by…

Initiation of the IMAGE1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in Q4 2021

The Berlin start-up uses AI to recognize post-operative complications before they become critical. IBB Ventures and several business angels have invested in the company.

As part of its ‘GO-Bio initial’ programme, the BMBF has awarded Ascenion funding for its 'Life Science Digital Hub' concept to improve support for GO-Bio initial applicants.

An innovative approach to combat infections caused by Staphylococcus aureus will receive funding of initially 1.33 million USD plus an additional 7.44 million USD, depending on project progress. It is jointly developed by the HZI and the LDC.

BERLIN, 28 August 2020 – Aignostics, a spin-off from Charité - Universitätsmedizin Berlin and the Berlin Institute of Health (BIH) pioneering…

• T-knife’s proprietary humanized mouse platform (HuTCR) T-cell Receptors expected to provide superior affinity/specificity properties
• Series A round led by Versant Ventures and RA Capital Management, with strong participation from seed investors Andera Partners and BIVF

Ascenion and Innovationsstarter Fonds Hamburg acquire equity in Hamburg start-up – innovative therapeutic approach enters clinical testing

Lead liver disease candidate to enter clinical trials this year

Simultaneously Closes Strategic Growth Investment from Ampersand Capital to Create a Leading Provider of Genomic and Cell and Tissue Analysis Products…

ISAR Bioscience is sponsor of BioVaria 2019, Europe’s leading showcasing event for life science technologies. ISAR is committed to translational R&D…

This is an exciting opportunity for European healthcare entrepreneurs, start-ups and SMEs: EIT Health invites you to apply for participation in the…

Three months following the first closing of its Series C financing, iThera Medical completed a second closing with Occident Ventures, BayBG and Falk…

Following the successful completion of a Phase I trial with its cardioprotective lead candidate OMT-28, OMEICOS has now closed a Series C financing…

iThera Medical, a spin-off from the Helmholtz Zentrum München, has closed series C financing with new investors FLUXUNIT, the corporate venture…

OMEICOS Therapeutics, a spin-off from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), announced the second closing…

Unique RNA-based approach for the treatment of heart diseases

11 May 2017, Munich – Cardior Pharmaceuticals has completed a EUR 15 million Series A…

A consortium of nine partners from five European countries, led by the Helmholtz Zentrum München, will work together with a transdisciplinary approach…

OMEICOS Therapeutics, a spin-off from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), announced the first closing…

Tubingen (Germany), January 05, 2017 – HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today…

amcure, a company that received support from Ascenion’s Spinnovator coaching program from the beginning, reports a significant milestone: At the end…

WIPANO (Wissenstransfer durch Patente und Normen: knowledge transfer via patents and standards) is the successor to SIGNO, and has been running since…

amcure, a spin-off from the Karlsruhe Institute of Technology (KIT), has received a further EUR 1.9 million funding from the German Federal Ministry…

Recent Publication in Key Scientific Journal Supports amcure’s Therapeutic Approach in Cancer

Ascenion’s portfolio company OMEICOS, a spin-off from the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, has received further funding of…